Association between BNT162b2 and CoronaVac vaccination and risk of CVD and mortality after COVID-19 infection: A population-based cohort study.

It is unknown if vaccination affects the risk of post-COVID-19 cardiovascular diseases (CVDs). Therefore, this retrospective cohort study examines the short-term and long-term risks of post-infection CVD among COVID-19 patients with different vaccination status utilizing data from electronic health databases in Hong Kong. Cox proportional hazards regression adjusted with inverse probability of treatment weighting is used to evaluate the risks of incident CVD (coronary heart disease, stroke, heart failure) and all-cause mortality in COVID-19 patients. Compared with unvaccinated patients, vaccinated patients have a lower risk of CVD and all-cause mortality, and the lowest risk is observed in those who completed three doses of vaccine. Similar patterns in the subgroups of different vaccine platforms, age, gender, Charlson comorbidity index, and disease severity are observed. These findings highlight a positive dose-response relationship between overall CVD risk reduction and the number of vaccine doses received.
Competing Interests: Declaration of interests E.Y.F.W. has received research grants from the Health Bureau of the Government of the Hong Kong Special Administrative Region and the Hong Kong Research Grants Council (RGC) outside the submitted work. F.T.T.L. has been supported by the RGC Postdoctoral Fellowship under the Hong Kong RGC and has received research grants from the Health Bureau of the Government of the Hong Kong Special Administrative Region outside the submitted work. C.S.L.C. has received grants from the Health Bureau of the Hong Kong Government, Hong Kong RGC, Hong Kong Innovation and Technology Commission, Pfizer, IQVIA, and Amgen and personal fees from PrimeVigilance outside the submitted work. X.L. has received research grants from the Health Bureau of the Government of the Hong Kong Special Administrative Region, research and educational grants from Janssen and Pfizer, internal funding from the University of Hong Kong, and consultancy fees from Merck Sharp & Dohme unrelated to this work. I.C.K.W. reports grants from Amgen, Bristol-Myers Squibb, Pfizer, Janssen, Bayer, GSK, Novartis, the Hong Kong RGC, the Hong Kong Health and Medical Research Fund in Hong Kong, National Institute for Health Research in the United Kingdom, the European Commission, and the National Health and Medical Research Council in Australia; consulting fees from IQVIA and World Health Organization; payment for expert testimony for Appeal Court of Hong Kong; and is a non-executive director of Jacobson Medical in Hong Kong and Therakind in the United Kingdom outside of the submitted work. E.W.C. reports grants from RGC (Hong Kong), Research Fund Secretariat of the Food and Health Bureau, National Natural Science Fund of China, Wellcome Trust, Bayer, Bristol-Myers Squibb, Pfizer, Janssen, Amgen, Takeda, and the Narcotics Division of the Security Bureau of the Hong Kong Special Administrative Region and a honorarium from Hospital Authority outside the submitted work.
(Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.)